Precisely Targeted Nano‐Controller of PD‐L1 Level for Non‐Small Cell Lung Cancer Spinal Metastasis Immunotherapy
Authors:
- 11 August 2022
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (20) , e2200938
Abstract
Although immune checkpoint inhibitors (ICIs) have been widely applied to treat non‐small cell lung cancer (NSCLC), a significant proportion of patients, especially those with spinal metastasis (NSCLC‐SM), are insensitive to anti‐programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) ICIs. A drug delivery nano‐controller of PD‐L1 that targets NSCLC‐SM can solve this problem, however, none have been developed to date. In this study, it is shown that integrin β3 (β3‐int) is strongly upregulated in NSCLC‐SM. Its inhibitor RGDyK promotes PD‐L1 ubiquitination, indicating the potential application of RGDyK as a new PD‐L1 inhibitor in nano‐controller and a targeting peptide for NSCLC‐SM treatment. According to the synergistic effect of photodynamic therapy and ICIs on T‐cell activation through the release of tumor antigens, RGDyK‐modified and zinc protoporphyrin (ZnPP)‐loaded mesoporous silicon nanoparticles (ZnPP@MSN‐RGDyK) are fabricated. The ZnPP@MSN‐RGDyK nanoparticles precisely target β3‐int to inhibit PD‐L1, exhibiting high photodynamic therapy efficiency, and excellent immunotherapeutic effects in an NSCLC‐SM mouse model. Collectively, the findings indicate that ZnPP@MSN‐RGDyK is a promising immunotherapeutic agent for treating NSCLC‐SM.Keywords
Funding Information
- National Natural Science Foundation of China (82172738, 81972508, 52103171)
- Natural Science Foundation of Shanghai Municipality (21ZR1412300)
This publication has 44 references indexed in Scilit:
- Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLCClinical Cancer Research, 2018
- Basolateral CD147 induces hepatocyte polarity loss by E‐cadherin ubiquitination and degradation in hepatocellular carcinoma progressHepatology, 2018
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer ImmunityCold Spring Harbor Perspectives in Biology, 2018
- Cancer-associated fibroblasts lead tumor invasion through integrin-β3–dependent fibronectin assemblyJournal of Cell Biology, 2017
- The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody BlockadeCancer Immunology Research, 2017
- Diverse gatekeepers for mesoporous silica nanoparticle based drug delivery systemsChemical Society Reviews, 2017
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder CancerClinical Cancer Research, 2017
- PD-1 blockade enhances the vaccination-induced immune response in gliomaJCI Insight, 2016
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitormAbs, 2016
- Synthesis and modification of monodisperse silica microspheres for UPLC separation of C60 and C70Analytical Methods, 2015